FDA warns India's Emcure Pharma, cites repeated data fudging at plant

MUMBAI (Reuters) - The U.S. Food and Drug Administration (FDA) has warned Indian generic drugmaker Emcure Pharmaceuticals, saying it repeatedly fudged test records at its plant in western India, in another case of a pharmaceutical firm in the country facing such action.